Ford Motor Company vs Viatris Inc — how do they compare? Ford Motor Company trades at $12.29 (market cap $48.85B), while Viatris Inc trades at $17.47 (market cap $20.03B). The key difference: Ford Motor Company is far larger — about 2.4× Viatris Inc's market cap, and Ford Motor Company pays the higher dividend (4.9%). Which is the better fit depends on your goals — on Pluang, investors hold Ford Motor Company for 104 Days and Viatris Inc for 57 Days on average.
| F | VTRS | |
|---|---|---|
Market Cap | $48.85B | $20.03B |
Volume | 57,748,965 | 14,109,977 |
Sector | Consumer Cyclical | Health |
52-Week High | $17.44 | $18.27 |
52-Week Low | $11.21 | $9.74 |
Typical Hold Time | 104 Days | 57 Days |
Enterprise Value | $180.81B | $32.15B |
Dividend Yield | 4.9% | 2.75% |
Signals from Pluang's Aura AI — not financial advice
Ford Motor Company (F) trades at $12.125, down 1.22% with a bearish technical outlook. The company reported mixed quarterly results, beating Q1 and Q2 2026 EPS estimates but missing Q4 2025. Recent news highlights a 6.6% Q3 sales decline due to model phase-outs and supplier issues affecting F-150 production. Cash flow improved in 2025 with $560M net inflow, but profitability remains challenged with negative net income margin of -3.93% and ROE of -18.31%.
Ford faces headwinds from declining sales and profitability challenges, though analyst consensus remains cautiously optimistic with a $15.90 price target. The stock offers value with low P/S (0.26) and P/E (11.21) ratios, but investors must weigh competitive pressures and execution risks against potential turnaround opportunities in hybrid vehicle adoption and commercial divisions.
Viatris (VTRS) trades at $17.49, down 0.29% with a bullish technical signal and strong recent earnings beats. The company shows improving operational cash flow of $2.32B in 2025 and positive revenue growth trends, though profitability remains challenged with negative net margins. Recent developments include FDA approval for WAKIX in Japan and consistent dividend payments, supporting the bullish analyst consensus with a $22.17 price target representing 27% upside potential.
The outlook remains cautiously optimistic with strong cash generation supporting shareholder returns, but investors face risks from persistent negative profitability and high debt levels. The stock offers value appeal with reasonable P/S and P/B ratios, though the elevated P/E ratio reflects current earnings challenges that need resolution for sustained re-rating.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Ford Motor Company designs, manufactures, and services cars and trucks. The Company also provides vehicle-related financing, leasing, and insurance through its subsidiary.
Read more on F →Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →